Kessler: FDA pre-emption is of no benefit to public
FDA pre-emption of "failure-to-warn" state lawsuits over drug risks does nothing to benefit the agency or the public and can prevent information that is helpful to the FDA, healthcare providers, and consumers from coming out, say commissioner David Kessler and Georgetown Law professor David Vladeck in the Georgetown Law Journal.
The e-mail address(es) that you supply to use this service will only be used to send the requested article.